Harwin Peter Evan's Form 4 filing
Apogee Therapeutics, Inc.APGE · filed Jul 17, 2023
- Accession no.
- 0001104659-23-081729
- Filed
- Jul 17, 2023, 8:00 PM ET
- Trade date
- Jul 13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $50.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director |
| Fairmount Healthcare Fund L.P.CIK 0001686157 | Director |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director |
| Fairmount Funds Management LLCCIK 0001802528 | Director |
| Kiselak TomasCIK 0001830177 | Director |
| Fairmount Healthcare Co-Invest II L.P.CIK 0001982189 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 13, 2023 | Common Stock | PPurchaseAcquired | +55,913 | $17.00 | +$950,521 | 55,913 | Indirect | |
| Jul 13, 2023 | Common Stock | PPurchaseAcquired | +1,992,734 | $17.00 | +$33,876,478 | 1,992,734 | Indirect | |
| Jul 13, 2023 | Common Stock | PPurchaseAcquired | +892,529 | $17.00 | +$15,172,993 | 892,529 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 13, 2023 | Common Stock | AGrant or awardAcquired | +47,758 | $0.00 | $0 | 47,758 | Direct | |
| Jul 13, 2023 | Common Stock | AGrant or awardAcquired | +47,758 | $0.00 | $0 | 47,758 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Fairmount, Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP may each be deemed a director by deputization of the Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of Fairmount.